These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7519627)

  • 21. Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.
    Balzarini J; Kleim JP; Riess G; Camarasa MJ; De Clercq E; Karlsson A
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1305-12. PubMed ID: 7517668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
    J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
    Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3,5,8-Trihydroxy-4-quinolone, a novel natural inhibitor of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2.
    Loya S; Rudi A; Tal R; Kashman Y; Loya Y; Hizi A
    Arch Biochem Biophys; 1994 Mar; 309(2):315-22. PubMed ID: 7510944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
    Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
    Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
    Fan N; Rank KB; Slade DE; Poppe SM; Evans DB; Kopta LA; Olmsted RA; Thomas RC; Tarpley WG; Sharma SK
    Biochemistry; 1996 Jul; 35(30):9737-45. PubMed ID: 8703945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
    Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA
    Biochemistry; 1995 Apr; 34(13):4346-53. PubMed ID: 7535561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E
    Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
    [No Abstract]   [Full Text] [Related]  

  • 32. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New type of HIV drug.
    Treat Rev; 1995 Nov; (no 20):4. PubMed ID: 11363022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.
    Dollé V; Fan E; Nguyen CH; Aubertin AM; Kirn A; Andreola ML; Jamieson G; Tarrago-Litvak L; Bisagni E
    J Med Chem; 1995 Nov; 38(23):4679-86. PubMed ID: 7473595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of interactions of DNA polymerase beta and reverse transcriptases of human immunodeficiency and mouse leukemia viruses with dNTP analogs containing a modified sugar residue.
    Lebedeva NA; Seredina TA; Silnikov VN; Abramova TV; Levina AS; Khodyreva SN; Rechkunova NI; Lavrik OI
    Biochemistry (Mosc); 2005 Jan; 70(1):1-7. PubMed ID: 15701045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by 3'-blocked oligonucleotide primers.
    Austermann S; Kruhøffer M; Grosse F
    Biochem Pharmacol; 1992 Jun; 43(12):2581-9. PubMed ID: 1378738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non-nucleoside inhibitors.
    Rubinek T; McMahon JB; Hizi A
    FEBS Lett; 1994 Aug; 350(2-3):299-303. PubMed ID: 7520874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic human tRNA(UUULys3) and natural bovine tRNA(UUULys3) interact with HIV-1 reverse transcriptase and serve as specific primers for retroviral cDNA synthesis.
    Weiss S; König B; Müller HJ; Seidel H; Goody RS
    Gene; 1992 Feb; 111(2):183-97. PubMed ID: 1371759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of enzyme inhibition mediated by anti-reverse transcriptase antibodies from HIV type 1-infected individuals.
    Devico AL; Rahman R; Sarngadharan MG; Veronese FD
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):953-60. PubMed ID: 7529034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.